REMEGEN (09995) released its annual performance, with shareholders' net profit reaching 709 million yuan, turning losses into gains compared to the previous year.

REMEGEN (09995) released the annual performance report for the year 2025. The company achieved a total operating income of 3.251 billion RMB, an increase of 89.36% year-on-year; net profit attributable to owners of the parent company was 709 million RMB, turning a loss into a profit year-on-year; basic earnings per share were 1.29 RMB. The announcement stated that the increase in operating income was mainly due to the increase in sales of the injection Taletuzumab and the injection Vedolizumab monospecific antibody, leading to an increase in sales revenue. In addition, the company granted Vor Biopharma Inc. exclusive development and commercialization rights for Taletuzumab worldwide except for the Greater China region, leading to a substantial increase in technology licensing revenue.